A detailed history of Norinchukin Bank, The transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Norinchukin Bank, The holds 85,936 shares of BMY stock, worth $4.93 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
85,936
Previous 72,739 18.14%
Holding current value
$4.93 Million
Previous $3.02 Million 47.25%
% of portfolio
0.11%
Previous 0.09%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $523,393 - $682,944
13,197 Added 18.14%
85,936 $4.45 Million
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $55,464 - $73,020
1,378 Added 1.93%
72,739 $3.02 Million
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $49,083 - $55,651
-1,023 Reduced 1.41%
71,361 $3.87 Million
Q4 2023

Feb 13, 2024

SELL
$48.48 - $57.85 $493,283 - $588,623
-10,175 Reduced 12.32%
72,384 $3.71 Million
Q3 2023

Nov 13, 2023

BUY
$57.89 - $64.73 $4.78 Million - $5.34 Million
82,559 New
82,559 $4.79 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $2.95 Million - $3.27 Million
46,265 Added 32.87%
187,008 $12 Million
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $270,593 - $306,914
4,118 Added 3.01%
140,743 $9.75 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $2.45 Million - $2.9 Million
-35,741 Reduced 20.74%
136,625 $9.83 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $2,732 - $1.62 Million
21,023 Added 13.89%
172,366 $12.3 Million
Q2 2022

Aug 10, 2022

SELL
$72.62 - $79.98 $3.76 Million - $4.15 Million
-51,839 Reduced 25.51%
151,343 $11.7 Million
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $762,720 - $914,570
12,406 Added 6.5%
203,182 $14.8 Million
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $76,154 - $88,778
-1,420 Reduced 0.74%
190,776 $11.9 Million
Q3 2021

Nov 09, 2021

BUY
$59.17 - $69.31 $435,077 - $509,636
7,353 Added 3.98%
192,196 $11.4 Million
Q2 2021

Aug 11, 2021

SELL
$61.91 - $67.42 $93,793 - $102,141
-1,515 Reduced 0.81%
184,843 $12.4 Million
Q1 2021

May 12, 2021

BUY
$59.34 - $66.74 $83,906 - $94,370
1,414 Added 0.76%
186,358 $11.8 Million
Q4 2020

Feb 12, 2021

SELL
$57.74 - $65.43 $316,068 - $358,163
-5,474 Reduced 2.87%
184,944 $11.5 Million
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $55,419 - $61,412
965 Added 0.51%
190,418 $11.5 Million
Q2 2020

Aug 12, 2020

SELL
$54.82 - $64.09 $481,264 - $562,646
-8,779 Reduced 4.43%
189,453 $11.1 Million
Q1 2020

May 13, 2020

SELL
$46.4 - $67.43 $8.46 Million - $12.3 Million
-182,350 Reduced 47.91%
198,232 $11 Million
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $4.65 Million - $6.06 Million
94,455 Added 33.01%
380,582 $24.4 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $270,049 - $320,182
6,314 Added 2.26%
286,127 $14.5 Million
Q2 2019

Aug 09, 2019

SELL
$44.62 - $49.34 $5.11 Million - $5.65 Million
-114,571 Reduced 29.05%
279,813 $12.7 Million
Q1 2019

May 10, 2019

BUY
$45.12 - $53.8 $505,659 - $602,936
11,207 Added 2.92%
394,384 $18.8 Million
Q4 2018

Feb 08, 2019

BUY
$48.76 - $63.23 $4.36 Million - $5.65 Million
89,338 Added 30.4%
383,177 $19.9 Million
Q3 2018

Nov 08, 2018

BUY
$55.19 - $62.25 $1.33 Million - $1.5 Million
24,132 Added 8.95%
293,839 $18.2 Million
Q2 2018

Aug 10, 2018

BUY
$50.53 - $62.98 $1.8 Million - $2.25 Million
35,690 Added 15.25%
269,707 $14.9 Million
Q1 2018

May 10, 2018

BUY
$59.92 - $68.98 $1.17 Million - $1.34 Million
19,461 Added 9.07%
234,017 $14.8 Million
Q4 2017

Feb 09, 2018

BUY
$59.94 - $65.35 $511,827 - $558,023
8,539 Added 4.14%
214,556 $13.1 Million
Q3 2017

Nov 08, 2017

BUY
$55.23 - $63.74 $11.4 Million - $13.1 Million
206,017
206,017 $13.1 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Norinchukin Bank, The Portfolio

Follow Norinchukin Bank, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norinchukin Bank, The, based on Form 13F filings with the SEC.

News

Stay updated on Norinchukin Bank, The with notifications on news.